Professor Paul Nathan is an internationally renowned consultant medical oncologist with HCA Healthcare at LOC, The Harley Street Clinic, and The Wellington Hospital. His NHS practice is based at Mount Vernon Cancer Centre and UCLH. Professor Nathan's clinical interests include melanoma of the skin, eye, and internal organs; kidney cancer (renal cell carcinoma), and rare skin cancers including Merkel cell carcinoma.

He originally trained in cancer immunology as a scientist, and following his Ph.D. and then post-doctoral position in Pittsburgh, he ran a tumor immunology laboratory in the pharmaceutical industry. He then pursued clinical studies at Cambridge and UCL. Professor Nathan has been a Consultant Medical Oncologist for over 20 years. He is heavily involved in research and is the lead investigator for many clinical trials, particularly in the field of immunotherapy and targeted therapies. Most recently he has led the development of tebentafusp, the first drug proven to improve survival in advanced uveal melanoma. Professor Nathan has published over 150 papers, many of which are in the world's leading medical journals, and has contributed to a number of medical textbooks. He is the Chair of the UK Uveal Melanoma Guidelines group and the UK Lead for Uveal Melanoma at the International Rare Cancer Initiative. He also leads melanoma systemic therapies for the European cancer organisation's (EORTC) melanoma group. Previously, Professor Nathan chaired the NCRI renal cancer clinical studies group.

Diseases, Medical Tests and Treatments

• Immunotherapy, Targeted Therapies, Chemotherapy
• Chemotherapy
• Urological Cancer
• Kidney Cancer
• Renal Cancer
• Skin Cancer
• Melanoma